Nonalcoholic steatohepatitis in children

Current Gastroenterology Reports

Volumn 5, Issue 3, 2003, Pages 253-259

  Roberts, Eve A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; BETAINE; METFORMIN; URSODEOXYCHOLIC ACID;

ACANTHOSIS NIGRICANS; ADOLESCENT; BODY MASS; CHILD; CLINICAL TRIAL; DIET THERAPY; DISEASE COURSE; EXERCISE; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; RISK ASSESSMENT; WEIGHT REDUCTION; AGE; FATTY LIVER; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FATTY LIVER; FEMALE; HUMANS; MALE; OBESITY; RISK FACTORS;

EID: 0037491475     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0028-4     Document Type: Review

References (50)

1. Adler M, Schaffner F: Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979, 67:811-816.
2. Ludwig J, Viggiano TR, McGill DB, Ott BJ: Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
3. Lee RG: Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989, 20:594-598.
4. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
5. Bacon BR, Farahwash MJ, Lanney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
6. Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
7. Teli MR, James OF, Burt AD, et al.: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
8. Powell EE, Cooksley WGE, Hanson R, et al.: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
9. Willner IR, Waters B, Patil SR, et al.: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol 2001, 96:2957-2961.
10. Charlton M, Kasparova P, Weston S, et al.: Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001, 7:608-614.
11. Ong J, Younossi ZM, Reddy V, et al.: Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001, 7:797-801.
12. Contos MJ, Cales W, Sterling RK, et al.: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001, 7:363-373.
13. Ratziu V, Bonyhay L, Di Martino V, et al.: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35:1485-1493.
14. Shimada M, Hashimoto E, Taniai M, et al.: Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002, 37:154-160.
15. Marchesini G, Brizi M, Morselli-Labate AM, et al.: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
16. Tankurt E, Biberoglu S, Ellidokuz E, et al.: Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999, 31:963.
17. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
18. Paradis V, Perlemuter G, Bonvoust F, et al.: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-744.
19. Pagano G, Pacini G, Musso G, et al.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35:367-372.
20. Chitturi S, Abeygunasekera S, Farrell GC, et al.: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
21. Cortez-Pinto H, Camilo ME, Baptista A, et al.: Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999, 18:353-358.
22. Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21:27-41.
23. Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
24. Festa A, D'Agostino R, Jr, Williams K, et al.: The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001, 25:1407-1415.
25. Pannacciulli N, Cantatore FP, Minenna A, et al.: C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001, 25:1416-1420.
26. Visser M, Bouter LM, McQuillan GM, et al.: Low-grade systemic inflammation in overweight children. Pediatrics 2001, 107:E13.
27. Decsi T, Molnar D, Koletzko B: Reduced plasma concentrations of alpha-tocopherol and beta-carotene in obese boys. J Pediatr 1997, 130:653-655.
28. Strauss RS: Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). J Pediatr 1999, 134:160-165.
29. Moran JR, Ghishan FK, Halter SA, Greene HL: Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983, 78:374-377.
30. Kinugasa A, Tsunamoto K, Furukawa N, et al.: Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gatroenterol Nutrit 1984, 3:408-414.
31. Vajro P, Fontanella A, Perna C, et al.: Persistent hypertransaminasemia resolving after weight reduction in obese children. J Pediatr 1994, 125:239-241.
32. Baldridge AD, Perez-Atayde AR, Graeme-Cooke F, et al.: Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995, 127:700-704.
33. Rashid M, Roberts EA: Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000, 30:48-53.
34. Manton ND, Lipsett J, Moore DJ, et al.: Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000, 173:476-479.
35. Kocak N, Yuce A, Gurakan F, Ozen H: Obesity: a cause of steatohepatitis in children. Am J Gastroenterol 2000, 95:1099-1100.
36. Sathya P, Martin S, Alvarez F: Nonalcoholic fatty liver disease (NAFLD) in children. Curr Opin Pediatr 2002, 14:593-600.
37. Molleston JP, White F, Teckman J, Fitxgerald JF: Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002, 97:2460-2462.
38. Strauss RS, Barlow SE, Dietz WH: Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000, 136:727-733.
39. Vajro P, Franzese A, Valerio G, et al.: Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000, 136:739-743.
40. Spieth LE, Harnish JD, Lenders CM, et al.: A low-glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 2000, 154:947-951.
41. Ludwig DS: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002, 287:2414-2423.
42. Goldfield GS, Epstein LH, Kilanowski CK, et al.: Cost-effectiveness of group and mixed family-based treatment for childhood obesity. Int J Obes Relat Metab Disord 2001, 25:1843-1849.
43. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734-738.
44. Marchesini G, Brizi M, Bianchi G, et al.: Metformin in nonalcoholic steatohepatitis. Lancet 2001, 358:893-894.
45. Hermanns-Le T, Hermanns JF, Pierard GE: Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002, 19:12-14.
46. Kay JP, Alemzadeh R, Langley G, et al.: Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001, 50:1457-1461.
47. Jones KL, Arslanian S, Peterokova VA, et al.: Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002, 25:89-94.
48. Nardo LG, Rai R: Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol 2001, 15:373-380.
49. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002, 87:1555-1559.
50. Angulo P, Lindor KD: Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001, 21:81-88.